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Children’s Hospital, University of Essen, Hufelandstr. 55, D-45122 Essen, Germany 
Concentrations of nitric oxide (NO) have been found to be reduced in both the upper and lower airway of patients 
with cystic fibrosis (CF). As NO modulates bronchomuscular tone, low NO levels may contribute to the obstructive 
lung disease in these patients. To assess whether increasing inspiratory NO concentrations has any impact on lung 
function, we have studied 13 CF patients aged 1438 years in a clinically stable condition and nine healthy controls. 
NO was applied via a mixing chamber for 5 min with NO concentrations of 100 parts per billion, 1 and 40 parts per 
million. Spirometry was performed at baseline and after inhalation on each occasion. 
There were no clinical side-effects at any NO concentration and no changes in oxygen saturation were observed. 
Lung function remained unchanged in all subjects throughout the study period. Sputum nitrate and nitrite 
concentrations before and after inhalation of high NO concentrations (40 ppm) in eight CF patients did not show 
any significant changes, even though a tendency to higher nitrate levels was observed (399 f 231 vs. 
556*474pmoll-I). Therefore, inhaled NO at either the physiological levels present in the upper airway of 
normal individuals or those used therapeutically to treat pulmonary hypertension has no immediate effect on 
bronchomuscular tone in patients with cystic fibrosis. 
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Introduction 
Lung disease in cystic fibrosis (CF) is characterized by 
chronic, neutrophil dominated airway inflammation (1). 
Despite high levels of pro-inflammatory cytokines, which 
are known to induce enzymes that produce nitric oxide 
(NO), recent studies have shown that NO concentrations in 
both upper and lower airways of CF patients are decreased 
(2,3). This may be due to reduced expression of the 
inducible NO synthase (NOS2) in CF epithelial cells, as 
recently reported (4,5). In addition, there is evidence for 
impaired function of bronchodilatory nerve fibres in CF 
which use NO as a neurotransmitter (6). 
inhalation of upper airway NO is important in maintaining 
bronchomuscular tone (14). Therefore, reduced concentra- 
tions of NO in the upper airway could potentially have a 
negative impact on the obstructive lung disease in CF. In 
this study, we assessed whether inhalation of NO in 
concentrations present in the upper airway of normal 
individuals as well as concentrations used therapeutically in 
diseases such as pulmonary hypertension have any impact 
on pulmonary function in CF patients. 
Material and Methods 
The pathophysiological significance of reduced NO 
formation in CF airways remains unclear. NO has a 
number of functions that may be relevant for CF lung 
disease. NO stimulates ciliary beating frequency (7) and is 
involved in neutrophil-mediated killing of Stuphylococcus 
aureus, a common pathogen in CF patients (8-10). 
In addition, NO is a potent vasodilator (11,12) and acts 
as a bronchodilator as shown by a reduced bronchocon- 
strictor response to metacholine after pre-treatment with 
NO (13). 
NO levels in the nose are loo-fold higher than in the 
lower airways and it has been postulated that auto- 
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Thirteen CF patients (median age: 16.5 years, range: 1439) 
and nine non-smoking healthy controls (median age 26.5 
years, range 24-37) were included in this study. The 
diagnosis of cystic fibrosis had been confirmed by repeated 
sweat test with chloride levels exceeding 60 mval 1-l. All 
patients were clinically stable at the time of study. None of 
the patients received corticosteroids; bronchodilators were 
withheld for at least 8 h prior to study. The controls were 
free of acute or chronic respiratory disease and had no 
history of or clinical evidence for hyperreactive airway 
disease. None of the controls received any medication. The 
study was approved by the ethics committee of our 
institution; written informed consent was obtained by all 
volunteers and patients or their parents. 
NO was applied via a mixing chamber (Loflo, Jlirfiilla, 
Sweden) which allowed supplementing NO to synthetic air 
containing 21% oxygen over a wide range of NO 
concentrations. The output of the mixing chamber was 
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connected to a mouth-piece via a three-way valve and to a 
3-l anaesthetic bag. In preliminary experiments we could 
demonstrate constant inspiratory NO as well as oxygen 
concentrations with this setting. The concentration of NO 
during inhalation was monitored continuously via a 
chemiluminescence analyser (NO 280, Sievers, Boulder, 
CA, U.S.A.). Subjects were instructed to perform normal 
tidal breathing over a period of 5 min. NO inhalations 
were performed with concentrations of 100 ppb, 1 ppm 
and 40 ppm, respectively, on 3 consecutive days in random 
order. 
Spirometry was performed at baseline on each day and 
immediately after inhalation of the NO gas mixture. 
Three forced expiratory manoeuvres from total lung 
capacity were performed on each occasion; the mean of 
the three measurements was taken for analysis. The 
primary outcome parameter was a change in forced 
expiratory volume in 1 set (FEVi) from baseline, but 
changes for forced vital capacity (FVC) and flows at 
lower lung volumes mid-expiratory flow [(MEF) 50 and 
25% of VC] were also included in the analysis. Oxygen 
saturation was monitored continuously during the experi- 
ments; blood pressure was measured before and after each 
experiment. 
To assess the amount of NO retained as stable 
degradation products in respiratory secretions, sputum 
was sampled before and after inhalation of 40 ppm NO. 
Sputum samples were diluted 1: 1 in aqua bidest and 
centrifuged at 200 g for 10 min after being homogenized 
in an ultrasound water bath as previously described (15). 
Clear supernatant was used for analysis. Nitrate was 
reduced to NO with vanadium III chloride (4 ml of a 
solution containing 800 mg vanadium III chloride, 8 ml of a 
37% solution of HCL and 100 ml of distilled water). The 
evolved NO was determined with a Sievers NO analyser by 
comparing results against a standard curve generated 
before each experiment. Similarly, nitrite was measured 
by reduction with 3 ml of acetic acid and 1 ml of a 5% 
solution of potassium iodide. Each test was performed in 
triplicate; the mean of three measurements was used for 
analysis. 
STATISTICAL ANALYSIS 
All data were tested for normal distribution with the 
Kolmogorov-Smirnov test. Results were expressed as mean 
* standard deviation (SD). The differences in pulmonary 
function and nitrate concentration in sputum before and 
after NO inhalation was assessed with the paired Student’s 
t-test. Linear regression analysis was used for the compar- 
ison of NO concentration in exhaled air and nitrate 
concentration in sputum. Changes in nitrate and nitrite 
concentration after incubation with NO were tested with 
analysis of variance (ANOVA). A P-value of less than 0.05 
was considered statistically significant. 
Results 
NO inhalation was well tolerated in all CF patients and 
control subjects. Oxygen saturation, heart rate and blood 
pressure remained unchanged during the inhalation period 
at all NO concentrations. 
The effect of NO inhalation in concentrations of 100 ppb, 
1 ppm and 40 ppm on pulmonary function in normal 
subjects and CF patients is displayed in Table 1. There were 
no changes in FEVi, FVC or flows at lower lung volumes 
for all NO concentrations in both healthy individuals and 
patients with CF. Individual response did not differ from 
the group overall and none of the subjects had a change in 
TABLE 1. Pulmonary function in cystic fibrosis (CF) patients and controls receiving different concentrations of inhaled nitric 
oxide 
100 ppb 1 mm 40 wm 
Pre Post Pre Post Pre Post 
Controls 
FVC (% predicted) 102.8 + 8.6 102.2+7-8 101.3k8.9 103.2+8.9 105*9+9*0 104.4+8.7 
FEVi 104.6k9.3 104.24 10.1 103.6+ 10.4 103*6& 10.4 106.5k9.9 105*0+ 10.5 
PEFR 101.9_+21.0 96.5 + 18.8 103*0+ 19.5 103.0+ 19.5 105*9f 19.7 103.9&-20.4 
MEF 50% VC 97.6f21.3 97.7k3.3 97.7*20.1 94.9f21.0 101.9f 15.8 97*0* 15.6 
MEF 25% VC 92.9 + 19.7 92.5k27.5 90.0+_20+2 91.9k21.1 93.4+_ 12.3 89.9k22.8 
Cystic fibrosis 
FVC (% predicted) 68.1 k21.9 69.5k23.8 67.5 + 17.9 66.4+ 19.7 71.7k21.3 73.3k21.5 
FEVr 58.Ok26.6 59.5 + 27.4 58.2k21.3 58.2 *21.9 60.8k23.7 61.5k23.7 
PEFR 63*6k22*5 64.6 + 22.5 67.5f28.4 65.9k26.1 68.4k22.0 67.8k26.2 
MEF 50 % VC 44.9 k43.3 45.2k41.2 44*5+35*3 42.5k33.7 40.1 k28.1 40.4*31*9 
MEF 25% VC 33.Ok31.6 30.5)24.4 28.6521.0 30.9+21.2 26.6k28.4 30*4+31.5 
ppb, parts per billion; ppm, parts per million. 
Abbreviations as in text. 
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any of the lung function parameters exceeding 10% of the 
baseline value. 
Sputum nitrate concentrations for eight patients 
who produced sufficient sputum material at baseline were 
similar to our results reported previously (15). There was a 
significant correlation between exhaled NO concentrations 
and sputum nitrate (r = O-83, P<O*O2, linear regression 
analysis) (Fig. 1). 
Sputum nitrate and nitrite concentrations before and 
after inhalation of high NO concentrations (40 ppm) did 
not show any significant changes, even though a tendency 
to higher nitrate levels was observed (399 5 231 vs. 556 f 
474 pm01 1-l). 
To study the dynamics of metabolization of NO to its 
stable degradation products nitrate and nitrite, we incu- 
bated sputum of five CF patients with room air containing 
40 ppm NO over a period of 5 min and measured nitrate 
and nitrite concentrations immediately after incubation, 
after 1, 3, 6 and 24 h. Compared to untreated specimens of 
the same individuals, nitrate concentrations remained 
unchanged over the observation period, a significant 
increase was observed in nitrite levels after 1 h of 
incubation (P<O*O5, ANOVA) which remained significant 
up to 6 h (Fig. 2). 
Discussion 
In a previous study we showed that r,-arginine, the substrate 
of NO synthases, given intravenously in a dose of 
500 mg kg-’ bodyweight, results in a small but significant 
increase in lower airway NO formation as reflected by 
increased NO concentrations in end-tidal exhaled air (16). 
However, even with these high doses of L-arginine, 
normalization of airway NO was not achieved and lung 
function remained unchanged. In the present study we 
have, therefore, tested whether inhaled NO has any 
bronchodilator effect in CF patients. The results of the 
present study demonstrate that neither the concentrations 
present in the upper airway of normal individuals or higher 
concentrations (40 ppm) that are used therapeutically for 
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FIG. 1. Exhaled NO concentrations and nitrate 
concentrations of sputum in seven CF patients. 
Measurements were obtained at baseline before the 
inhalation of NO. Each point represents one individual. A 
positive correlation was observed between NO in exhaled 
air and its stable degradation product nitrate in sputum 
(P = 0.02, r = 0.82, linear regression analysis). 
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FIG. 2. Changes in nitrite concentrations in sputum 
after incubation with 40 ppm NO (A) compared 
to untreated sputum specimens (a). The mean and SEM 
are displayed before incubation (0), after 10 minutes, 1, 
3,6 and 24 h. A significant increase was observed after 1 h 
which remained elevated up to 6 h (*P<O*O5; ANOVA). 
pulmonary hypertension have any effect on pulmonary 
function in patients with cystic fibrosis. Therefore, the low 
levels of NO in airways of CF patients appear to be of no 
relevance for the control of bronchomuscular tone in CF 
patients 
The effect of inhaled NO on bronchomuscular tone has 
been studied before in animal models with metacholine- 
induced bronchoconstriction and in adult subjects with and 
without hyperreactive airway disease (13,17,18). While 
inhaled NO in a dose of 80 ppm had no effect on 
metacholine-induced bronchoconstriction in normal indivi- 
duals, a bronchodilatory effect was seen in subjects with 
hyperreactive airways and/or asthma (13). This effect was, 
however, less pronounced than that achieved by p2- 
agonists. While we could confirm previous findings that 
NO has no effect on resting bronchomuscular tone in 
normal individuals, this also appears to be the case in cystic 
fibrosis, where NO formation is reduced. 
Due to the secretion barrier, inhaled NO may not reach 
the bronchial smooth muscle cells in CF. This is, however, 
unlikely as inhaled NO used therapeutically for pulmonary 
hypertension can easily cross the alveolar membrane and 
reach the muscular layer of arterioles (19). In addition, 
protection against histamine-induced bronchoconstriction 
has been described in asthmatic subjects who also have an 
increased diffusion barrier due to airway oedema (13). 
While retention of NO within respiratory secretions may 
limit the concentrations in the lower airways in CF, our 
data on NO metabolites in sputum would not support that 
this deposition of NO within the airway secretion alone can 
explain the lack of effect of inhaled NO on pulmonary 
function in CF patients. 
We have chosen a maximal NO concentration of 40 ppm 
which is known to be effective in lowering pulmonary 
vascular tone and is also reported to be safe (20). In the 
presence of oxygen, NO is metabolized to NOz which is a 
toxic gas at concentrations exceeding 5 ppm. Based on 
theoretical calculations, this concentration is reached within 
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13 min at 21% oxygen and 40 ppm, but in only 3 rnin, if 80 
ppm of NO are applied (21,22). In addition, other potentially 
harmful toxic metabolites such as nitrous acid, nitric acid and 
peroxynitrite may be formed and retained in respiratory 
secretion (23). Although we cannot exclude the possibility 
that NO concentrations higher than 40 ppm may have some 
effect on bronchomuscular tone, we would not test their 
efficacy unless their safety has been clearly demonstrated. 
The time-course of oxidation of NO to its stable 
metabolites, nitrate and nitrite, within CF airways has not 
been defined. Dynamics of increase in sputum NO 
metabolites are not only influenced by the concentrations 
of NO and oxygen but may also be altered by respiratory 
diseases due to the presence of sputum. Sputum has 
recently been shown to have a rather low oxygen tension 
(24). Although we have previously found elevated concen- 
trations of nitrate and nitrite in sputum of CF patients (15), 
this metabolization may take longer than that chosen for 
sputum collection in the present study (10 min). This is 
supported by our in vitro measurements, where nitrite 
concentrations were unchanged immediately after incuba- 
tion with 40 ppm NO but increased significantly after 1 h. 
In addition to its effect on airway and vascular smooth 
muscle cells, NO has multiple functions which are 
potentially relevant for CF lung disease. Nitric oxide 
stimulates ciliary beating frequency and low NO levels in 
the airway could thus impair mucociliary clearance (7). NO 
has antimicrobial activities and is needed for neutrophil- 
mediated killing of S. aureus, a common pathogen in CF 
lung disease (9,25). Finally, NO has been shown to activate 
CFTR, thereby increasing chloride current through epithe- 
lial cells (26,27). The relevance of these functions for 
patients with cystic fibrosis has not been defined. While our 
data show that the increasing NO in inspired air has no 
immediate effect on lung function of CF patients, other 
aspects mediated by NO may still be functionally relevant 
for CF lung disease. 
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